D-0366-2022 Class II Terminated

Recalled by RemedyRepack Inc. — Indiana, PA

FDA drug recall D-0366-2022 was initiated by RemedyRepack Inc. on Dec 30, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. The recall status is terminated (terminated Mar 28, 2022). Affected quantity: 56 Blister Cards.

Recall details

Product Type
Drugs
Report Date
Jan 19, 2022
Initiation Date
Dec 30, 2021
Termination Date
Mar 28, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
56 Blister Cards

Product description

Metformin 750 mg Extended Release NDC # 70518-2920-00

Reason for recall

CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

Distribution pattern

Product was distributed to one direct account in PA.

Code information

Lot # J0511265-021121, exp. date 02/28/2022 J0499451-122220, exp. date 01/31/2022 J0496563-120820, exp. date 12/31/2021 J0495111-120120, exp. date 12/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0366-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0366-2022. Report a data issue: hello@regdatalab.com.